-
- COVID-19
Jan 22, 2025Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. received approval for a new drug application in Taiwan and signed a government stockpiling agreement -
- SARS-CoV-2
Oct 15, 2024Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1. -
- SARS-CoV-2
Feb 16, 2024Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant -
- SARS-CoV-2
Jan 16, 2024Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1 -
- SARS-CoV-2
Dec 19, 2023Viral uptake and pathophysiology of the lung endothelial cells in age-associated severe SARS-CoV-2 infection models -
- flavivirus
Nov 14, 2023Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain -
- SARS-CoV-2
Oct 17, 20232-thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses -
- PD-L1
Oct 05, 2023Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours -
- COVID-19
Sep 25, 2023Collaboration with Shionogi for drug discovery – COVID-19 treatment drug “Xocova” effect on Long COVID -
- COVID-19
Jul 07, 2023Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study -
- Mincle
Jun 26, 2023Structural basis for plastic glycolipid recognition of the C-type lectin Mincle -
- CIITA
- MHC class II
- T cells
Jun 08, 2023FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA
